Novel Drug Tied to Slowed Disease Progression in Relapsing MS
NATIONAL HARBOR, Maryland — Ublituximab (TG Therapeutics, Inc), an investigational anti-CD20 monoclonal antibody infused once every 6 months, is effective for treating relapsing forms of multiple sclerosis (RMS), new research suggests. Pooled analysis of the phase 3 ULTIMATE I and II trials, including more than 1000 total patients with RMS, showed significant improvements on several measures of disability progression for […]
» Read more